W
ABMD

Wealthfront’s Abiomed Inc ABMD Stock Holding History

Wealthfront’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$700K Buy
1,557
+8
+0.5% +$3.15K 0.01% 329
2018
Q2 		$634K Buy
1,549
+623
+67% +$226K 0.01% 331
2018
Q1 		$269K Buy
+926
New +$235K ﹤0.01% 454
2015
Q4 		– Sell
-297
Closed -$28K – 1153
2015
Q3 		$28K Buy
297
+145
+95% +$12.8K ﹤0.01% 652
2015
Q2 		$10K Buy
152
+52
+52% +$3.46K ﹤0.01% 851
2015
Q1 		$7K Buy
+100
New +$5.43K ﹤0.01% 722

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wealthfront's ABMD Position: Q3 2018 in Review

Wealthfront increased its Abiomed Inc (ABMD) stake by 0.52% in Q3 2018, buying an estimated $3.15K and bringing the position to 1,557 shares worth $700K. The position accounts for 0.01% of the portfolio, ranked #329.

Wealthfront first reported a position in ABMD in Q1 2015 and has held it in 6 quarters since. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

  • Wealthfront held 1,557 shares of Abiomed Inc worth $700K as of Q3 2018.
  • Wealthfront bought 8 Abiomed Inc shares in Q3 2018, an estimated $3.15K.
  • Abiomed Inc made up 0.01% of Wealthfront's portfolio in Q3 2018, its #329 holding.
  • Wealthfront first reported a position in Abiomed Inc in Q1 2015 and has held it in 6 quarters since.
  • 529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Wealthfront's 13F filing for Q3 2018, filed 13 Nov 2018.